41. Clinical benefit table: NRD‐101 (Suvenyl) versus Artz. Dichotomous outcome measu.

Study	TIme	Treatment	Outcome	No. improved	No. of pts.	Risk (%)	Risk difference	NNT
Yamamoto 1994	1‐4 wk	E: NRD‐101	Spontaneous pain (number of patients improved)	48	67	72	11	9.1
		C: Artz		43	70	61
Yamamoto 1994	1‐4 wk	E: NRD‐101	Pain during night (number of patients improved)	39	54	72	‐2	50
		C: Artz		39	53	74
Yamamoto 1994	1‐4 wk	E: NRD‐101	Pressure pain (number of patients improved)	60	94	64	7	14.3
		C: Artz		48	84	57
Yamamoto 1994	1‐4 wk	E: NRD‐101	Passive movement pain (number of patients improved)	31	53	58	‐8	12.5
		C: Artz		57	86	66
Yamamoto 1994	1‐4 wk	E: NRD‐101	Number of patients good/very good	50	81	62	2	50
		C: Artz		43	72	60